James Smitherman, MD
Orthopaedic Surgery · Madison, MSNPI 1114934643
Payments from drug & device makers
What this record shows
This record is dominated by education: $2,461 of the $3,145 with a category attached, or 78.2%. ALON Medical Technology accounts for 78.6% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2021 at $1,399 and has fallen 96.0% since, to $56 in 2025. That places this record below the midpoint for orthopaedic surgery clinicians in MS, where the typical reported total is $3,357.
Across 37 payments — averaging $85.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ALON Medical Technology$2K
- Pacira Therapeutics, Inc.$156
- Kerecis Limited$66
- Baudax Bio Inc.$64
- Nevro Corp.$53
- Pacira Pharmaceuticals Incorporated$45
- plus $288 from 13 others
What the payments were for
- Food & beverage$68422%
- Education$2,46178%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ALON Medical Technology | 3 | $2,473 |
| Pacira Therapeutics, Inc. | 9 | $156 |
| Kerecis Limited | 2 | $66 |
| Baudax Bio Inc. | 3 | $64 |
| Nevro Corp. | 2 | $53 |
| Pacira Pharmaceuticals Incorporated | 2 | $45 |
| Bioventus LLC | 2 | $41 |
| Johnson & Johnson(2 entities) | 2 | $40 |
| Amgen | 2 | $30 |
| Boston Scientific | 1 | $25 |
| Stryker | 1 | $23 |
| Philips North America LLC | 1 | $21 |
| Radius Health, Inc. | 1 | $21 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Vertex | 1 | $17 |
| Solventum Corporation | 1 | $17 |
| Heron Therapeutics, Inc. | 1 | $13 |
| Smith+Nephew | 1 | $13 |
| Fidia Pharma USA Inc. | 1 | $10 |
How this compares
$3,145 in reported general payments places this provider in the 45th percentile of 170 orthopaedic surgery providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Meloxicam | 639 | $1,811 |
| Methylprednisolone | 189 | $1,175 |
| Ondansetron OdtOndansetron | 65 | $1,043 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 68 | $835 |
| Naproxen | 94 | $531 |
| Celecoxib | 21 | $329 |
| Diclofenac Sodium | 14 | $211 |
| Gabapentin | 20 | $118 |
| Tramadol Hcl | 18 | $63 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Madison
- Peter MittwedeMadison$12K
- Matthew GravesJackson$1.2M
- George van OstenTupelo$322K
- Edward HobgoodJackson$267K
- Hanna MitiasNew Albany$249K
- Stephen SouthworthTupelo$160K
- Jamey BurrowJackson$130K
- Jeff AlmandJackson$109K
- Spencer MontgomeryJackson$90K
- Larry FieldJackson$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.